-
公开(公告)号:US20190153055A1
公开(公告)日:2019-05-23
申请号:US16097572
申请日:2017-04-19
申请人: YUHAN CORPORATION
发明人: Su Youn Nam , Jong Gyun Kim , Byung Hyun Choi , June Hyung Lee , Ju Young Park , Jun Kyung Lee , Na Rae Lee , Ki Hong Kim , Seul Gi Kim , Se Woong Oh , Seung Yub Shin , Ho Woong Kang , Su Jin Ahn , Soo Yong Chung
摘要: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.
-
公开(公告)号:US11046742B2
公开(公告)日:2021-06-29
申请号:US16097572
申请日:2017-04-19
申请人: YUHAN CORPORATION
发明人: Su Youn Nam , Jong Gyun Kim , Byung Hyun Choi , June Hyung Lee , Ju Young Park , Jun Kyung Lee , Na Rae Lee , Ki Hong Kim , Seul Gi Kim , Se Woong Oh , Seung Yub Shin , Ho Woong Kang , Su Jin Ahn , Soo Yong Chung
IPC分类号: C07K14/52 , C07K19/00 , C12N15/09 , C12N15/11 , C12N15/63 , A61K38/19 , A61K47/68 , A61P35/00 , A61K38/00 , A61K47/50
摘要: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.
-
公开(公告)号:US11505603B2
公开(公告)日:2022-11-22
申请号:US16970351
申请日:2019-02-28
申请人: YUHAN CORPORATION
发明人: Kwang-Hoon Lee , June Hyung Lee , Na Rae Lee , Eunjeong Jeong , Young Bong Park , Nakho Chang , Eun-Jung Lee , Ki Hong Kim , Sunghyun Choi , Byung Hyun Choi , Ju Young Park , Moo Young Song , Jong-Seo Lee , Kyu-Tae Kim , Bong-Kook Ko
IPC分类号: A61K39/395 , C07K16/00 , C07K16/46 , C07H21/04 , C12N5/02 , C12N5/20 , C12N15/00 , C07K16/28 , A61K39/00
摘要: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition.
The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.
-
-